PDX Pharmaceuticals has developed a patented nanoparticle platform (Pdx-NP™) that addresses the limitations of lipid nanoparticles in delivering therapeutics outside the liver upon systemic administration. Due to its capability to co-deliver various therapeutic classes (e.g., oligonucleotides, peptides, adjuvants, chemotherapeutics, small molecules, antibodies, cytokines, and other proteins), our platform has been utilized to create several product candidates. These therapeutic candidates do not only target cancer cells, but also stimulate anti-tumor immune response leading to cures and lack of recurrence in animal models of various tumor types. Our therapeutic candidates also enhance the level of cancer-specific T cells in the body without requiring ex vivo processing used in adoptive cell therapy. The technology has been validated through numerous high-impact publications, six issued US patents, and over $10 million in grants from the NCI, along with a $3.5 million seed investment.